Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice
Authors:
- Jyoji NakagawaraJNJyoji Nakagawara
- for J-MARS InvestigatorsFIfor J-MARS Investigators
- 1 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 41 (9) , 1984-1989
Abstract
Background and Purpose— In Japan, alteplase at 0.6 mg/kg was approved in October 2005 for use within 3 hours of stroke onset by the Ministry of Health, Labor and Welfare (MHLW). The aim of the Japan post-Marketing Alteplase Registration Study (J-MARS), which was requested by MHLW at the time of approval, was to assess the safety and efficacy of 0.6 mg/kg alteplase in routine clinical practice for the Japanese. Methods— A total of 7492 patients from 942 centers were enrolled in the J-MARS, an open-label, nonrandomized, observational study, from October 2005 to October 2007. Primary outcome measures were symptomatic intracranial hemorrhage (a deterioration in NIHSS score ≥4 from baseline) and favorable outcome (modified Rankin Scale score, 0–1) at 3 months after stroke onset. Results— The proportion of patients with symptomatic intracranial hemorrhage in 7492 patients (safety analysis) was 3.5% (95% confidence interval [CI], 3.1%–3.9%) within 36 hours and 4.4% (95% CI, 3.9%–4.9%) at 3 months. The overall mortality rate was 13.1% (95% CI, 12.4%–13.9%) and the proportion of patients with fatal symptomatic intracranial hemorrhage was 0.9% (95% CI, 0.7%–1.2%). The outcomes at 3 months were available for 4944 patients and the proportion of favorable outcome (efficacy analysis) was 33.1% (95% CI, 31.8%–34.4%). The subgroup analysis in patients between 18 and 80 years with a baseline NIHSS score Conclusions— These data suggest that 0.6 mg/kg intravenous alteplase within 3 hours of stroke onset could be safe and effective in routine clinical practice for the Japanese.Keywords
This publication has 17 references indexed in Scilit:
- Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery OcclusionStroke, 2010
- Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese PatientsStroke, 2009
- Outline of the Japanese Guidelines for the Management of Stroke 2004 and Subsequent RevisionInternational Journal of Stroke, 2008
- Guidelines for the Early Management of Adults With Ischemic StrokeStroke, 2007
- Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of OnsetStroke, 2006
- Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness StudyCanadian Medical Association Journal, 2005
- European Stroke Initiative Recommendations for Stroke Management – Update 2003Cerebrovascular Diseases, 2003
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Clinical Efficacy and Safety of Intravenous Tissue Plasminogen Activator in Acute Embolic Stroke: A Randomized, Double-Blind, Dose-Comparison Study of Duteplase1995
- Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic StrokeCerebrovascular Diseases, 1993